Published in Gene Therapy Weekly, June 6th, 2002
IP-10 is an antiangiogenic chemokine. When expressed by the parvovirus MVMp, the novel gene therapy MVMp/IP-10 diminishes the size of tumors implanted into mice with competent immune systems. The investigators, who work at major research institutes in Germany and Italy, believe that by extrapolation comparable gene therapy delivered by parvoviruses would reduce the size of highly vascular tumors in humans.
"Intratumoral/intraperitoneal administration of only 3x107 replication units of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.